drugset / Trial / NCT06489015
Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin in patients with mild to moderate Alzheimer's Disease (AD).
Timeline
- Start
- 2024-08-27
- Primary completion
- 2026-04-14
- Completion
- 2026-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED | Protein / enzyme biologic | 20 g | Intravenous |
| Subject | HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED | Protein / enzyme biologic | 30 g | Intravenous |
| Subject | HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED | Protein / enzyme biologic | 40 g | Intravenous |